FDA approvals - December 2025
The winter batch of FDA approvals featured therapies that compress intervention into fewer doses, fewer visits, and fewer points of failure.
Featured
FDA Approvals - November 2025
Mitochondrial disease and mutant leukemias signal where specialty pharma is placing its biggest bets.
Four years of progression-free survival: Nuvation Bio wins FDA approval for lung cancer
With a median progression-free survival nearing four years in ROS1 lung cancer, Nuvation Bio’s breakthrough therapy signals a turning point for precision oncology - validating Dr. David Hung’s patient-first vision.
FDA approvals - September 2025
September’s FDA approvals signaled shifting rules in biopharma - faster launches, smarter formulations, and bold plays from rising innovators and the familiar giants.
New CEO of Kindbody David Stern is in the business of building families
“Fifteen to twenty years ago, a woman under 35 had a 20% chance of live birth per IVF cycle. At Kindbody, today, it’s greater than 50%,” David Stern credits lab innovation and AI for rewriting fertility’s odds.
From sickness to prevention: How welfare cuts risk undermining the UK's 10-Year Health Plan
“Preventative care spending fell from 14.1% to just 5.2% of Government healthcare spending.” Ben Phillips warns that welfare reforms could widen existing health gaps.
Moloch and Medicine: why good intentions built a broken system, and why CGT might fix it all (sort of)
Anis Fahandej-Sadi breaks down the big problems with current incentive structures
When is JPM Week 2026?
All the details on when the 44th annual J.P. Morgan Healthcare Conference takes place!
Martial law targets resident physicians: implications for the healthcare crisis in South Korea
Industrial relations between doctors and the state have never been worse
We all want our hospital records in one place. Is Novellia the app to do it?
Shashi Shankar explains how his app unifies patients' scattered medical records all together, and what that has to do with the 21st Century Cures Act.
Backed by AstraZeneca, this company is helping radioligand cancer therapies hit the shelves
"Think of us as a critical partner in the ecosystem, ensuring that brilliant innovation doesn’t get stuck in the development phase but actually reaches the patients who need them."
NVIDIA’s Biggest Bet Yet: How Recursion Is Powering a New Era of AI-Driven Drug Discovery
“Almost all of the data that we use comes from our own laboratories - data generation doing real experiments in human biology… The AI side of things will be commoditized eventually, and the winners will be those who have the strongest data moat in life sciences.”
Alphabet's Verily is the future of precision and public health
We spoke with Stephen Gillett, Alphabet’s health-tech boss on life, leadership and AI.
Inside the world’s most innovative square mile: MassBio leads the life sciences
Kendalle Burlin O’Connell tells us about the privilege of heading up MassBio - the organization that represents the extraordinary life sciences sector in Massachusetts.